%PDF-1.4
%
74 0 obj
<>
endobj
71 0 obj
<>
endobj
148 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-09-13T13:37:23Z
2024-03-29T04:49:01-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-29T04:49:01-07:00
application/pdf
Heather
2003-463.oct
uuid:ffafb7dc-1dd1-11b2-0a00-dc0927bd7200
uuid:ffafb7df-1dd1-11b2-0a00-880000000000
endstream
endobj
60 0 obj
<>
endobj
61 0 obj
<>
endobj
75 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 42 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 44 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 46 0 R/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 48 0 R/Type/Page>>
endobj
25 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 50 0 R/Type/Page>>
endobj
33 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 52 0 R/Type/Page>>
endobj
36 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 54 0 R/Type/Page>>
endobj
174 0 obj
[178 0 R]
endobj
175 0 obj
<>stream
q
0 0 612 783 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6283 0.7779 -0.7779 0.6283 8.2321 49.765 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 783 m
0 783 l
f
q
-1 784 587 -785 re
W n
q
0 783.03 612 -783 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 63.4 732.5293 Tm
(Ann Rheum Dis 2003;62:1218-20.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(26.)-875.1 (Braun J, Brandt J, Listing J, et al. )17.7 (T)35 (reatment of active ankylosing)]TJ
2.175 -1.25 Td
(spondylitis with infliximab: a randomised controlled multicentre)Tj
0 -1.25 TD
[(trial. Lancet 2002;359:1)36.8 (187-93.)]TJ
-2.175 -1.25 Td
[(27.)-875.1 (Braun J, Brandt J, Listing J, et al. Long-term ef)17.7 (ficacy and safety of)]TJ
2.175 -1.25 Td
(infliximab in the treatment of ankylosing spondylitis: an open,)Tj
T*
(observational, extension study of a three-month, randomized,)Tj
T*
[(placebo-controlled trial. )54.8 (Arthritis Rheum 2003;48:2224-33.)]TJ
-2.175 -1.25 Td
[(28.)-875.1 (Amor B, Dougados M, Mijiyawa M. Criteria of the classification of)]TJ
2.175 -1.25 Td
(spondylarthropathies. Rev Rhum Mal Osteoartic 1990;57:85-9.)Tj
-2.175 -1.25 Td
[(29.)-875.1 (Amor B, Dougados M, Listrat )17.7 (V)128.9 (, et al. Evaluation of the )54.8 (Amor)]TJ
2.175 -1.25 Td
(criteria for spondylarthropathies and European Spondylarthropathy)Tj
T*
[(Study Group \(ESSG\). )54.8 (A)-220.1 (cross-sectional analysis of 2,228 patients.)]TJ
T*
(Ann Med Interne 1991;142:85-9.)Tj
-2.175 -1.25 Td
[(30.)-875.1 (Calin )54.8 (A, Elswood J. )17.7 (The natural history of juvenile-onset )]TJ
2.175 -1.25 Td
[(ankylosing spondylitis: a 24-year retrospective case-control study)64.8 (.)]TJ
T*
(Br J Rheumatol 1988;27:91-3.)Tj
-2.175 -1.25 Td
[(31.)-875.1 (Garcia-Morteo O, Maldonado-Cocco JA, Suarez-Almazor ME,)]TJ
2.175 -1.25 Td
[(Garay E. )54.8 (Ankylosing spondylitis of juvenile onset: comparison with)]TJ
T*
(adult onset disease. Scand J Rheumatol 1983;12:246-8.)Tj
-2.175 -1.25 Td
[(32.)-875.1 (Hornef)17.7 (f G, Bur)17.7 (gos-V)110.7 (ar)17.7 (gas R. )17.7 (TNF-)]TJ
/T1_2 1 Tf
0 Tc 0 Tw [-0.2 (\002)]TJ
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 17.2759 0 Td
(antagonists for the treatment)Tj
-15.1009 -1.25 Td
(of juvenile-onset spondyloarthritides. Clin Exp Rheumatol 2002;20)Tj
0 Tc T*
(Suppl 28:S137-42.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(33.)-875.1 (Baeten D, Kruithof E, )17.7 (V)110.8 (an den Bosch F)79.7 (, et al. Immunomodulatory)]TJ
2.175 -1.25 Td
[(ef)17.7 (fects of anti-tumor necrosis factor alpha therapy on synovium in)]TJ
T*
(spondylarthropathy: histologic findings in eight patients from an)Tj
T*
[(open-label pilot study)64.8 (. )54.8 (Arthritis Rheum 2001;44:186-95.)]TJ
30.825 32.5 Td
[(34.)-875.1 (Zou J, Rudwaleit M, Brandt J, )17.7 (Thiel )54.8 (A, Braun J, Sieper J. )]TJ
2.175 -1.25 Td
[(Down-regulation of the nonspecific and antigen-specific )17.7 (T)-257.1 (cell)]TJ
T*
(cytokine response in ankylosing spondylitis during treatment with)Tj
T*
[(infliximab. )54.8 (Arthritis Rheum 2003;48:780-90.)]TJ
-2.175 -1.25 Td
[(35.)-875.1 (Jimenez-Balderas FJ. Cuadro clinico de al espondilitis anquilosante)]TJ
2.175 -1.25 Td
(en el caucasocp y en el mestizo mexicano. Rev Mex Rheumatol)Tj
0 Tc 0 Tw T*
(1989;4:17.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(36.)-875.1 (Bur)17.7 (gos-V)110.7 (ar)17.7 (gas R, Naranjo )54.8 (A, Castillo J, Katona G. )54.8 (Ankylosing)]TJ
2.175 -1.25 Td
(spondylitis in the Mexican mestizo: patterns of disease according to)Tj
T*
(age at onset. J Rheumatol 1989;16:186-91.)Tj
-2.175 -1.25 Td
[(37.)-875.1 (Maksymowych )17.7 (WP)110.7 (, Gorodezky C, Olivo )54.8 (A, et al. HLA-DRB1*08)]TJ
2.175 -1.25 Td
(influences the development of disease in Mexican Mestizo with)Tj
T*
[(spondyloarthropathy)64.9 (. J Rheumatol 1997;24:904-7.)]TJ
-2.175 -1.25 Td
[(38.)-875.1 (U.S. Census Bureau, P145H. Sex by age \(Hispanic or Latino\) [49])]TJ
2.175 -1.25 Td
(\321 Universe: Hispanic or Latino population. Data Set: Census 2000)Tj
T*
(Summary File 3 \(SF 3\) \321 Sample Data. 2000. [Cited July 15,)Tj
T*
[(2004]. http://factfinder)54.8 (.census.gov/servlet/DTT)69.7 (able?_bm=y&-)]TJ
0 Tw T*
(context=dt&-ds_name=DEC_2000_SF3_U&-mt_name=DEC_)Tj
T*
(2000_SF3_U_P145H&-CONTEXT=dt&-tree_id=403&-)Tj
T*
(all_geo_types=N&-geo_id=05000US06019&-)Tj
T*
(geo_id=05000US06037&-format=&-_lang=en)Tj
0.02499 Tw -2.175 -1.25 Td
[(39.)-875.1 (Census of Population and Housing, 2000 [California]: Hispanic or)]TJ
2.175 -1.25 Td
(Latino by specific origin. Summary File 1 [on-line data)Tj
T*
[(file]/prepared by the California Digital Library)64.8 (, Oakland,)]TJ
T*
(California: [producer and distributor]. 2001. [Cited May 31, 2004].)Tj
0 Tw T*
[(http://countingcalifornia.cdlib.or)17.7 (g/matrix/c1)36.8 (18.html)]TJ
/T1_3 1 Tf
0.02499 Tw -35.4875 -53.5681 Td
[(Henrickson and Reiff: Etaner)36.8 (cept for JAS)]TJ
0 Tc 0 Tw 60.9375 -0.0313 Td
(2061)Tj
ET
0 0 0 1 K
44 72 m
548 72 l
S
0 0 0 0 k
/GS0 gs
97.22 76.74 396.48 -10.83 re
f*
0.5 w
97.22 76.74 396.48 -10.83 re
S
Q
Q
q
0 0 612 783 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
110.368 69 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 8 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
54 0 obj
<>stream
8;Z\5>Ah>4%+G/.W9XkO/X!-qA69MH+!T9FW"kbq*cZ,r2pBO,Y63>FlRY4Ek'5m"
YK5BllB9?`-\IN3qg'PX=]hKW``=[P"3tTMeKMrbr9`W
)GV##h6du]Ef>8;j;3u/j4mbV::/A62e9j?<8A4XC<-\PB`^g(1sHu%9rO+-Uuedca*?f/O6BrEQc9D8kB*E'sOuPX2rSI
,GbsSN?<7*MXqV*QG48-N-"WF^+&,(WT12\q[@l*KGA/j*6Eef@l;lW\6:L:93s?,
%P4n&K](:Lj;2sW2--,\=SJ!WT'njN+N*F0/[?na"Y5p=kI_lUNCK\jBJ^We7\eB+
,1q[\KsDm?J+M1&$p$uFDf.DG'L)["b*tss~>
endstream
endobj
58 0 obj
[/Indexed/DeviceRGB 255 57 0 R]
endobj
57 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
133 0 obj
<>
endobj
81 0 obj
<>
endobj
90 0 obj
<>
endobj
77 0 obj
<>
endobj
118 0 obj
<>
endobj
153 0 obj
<>
endobj
78 0 obj
<>
endobj
111 0 obj
<>stream
HPSWㅇbiWZWQQtA $@GH@@$ @
,*E+*̺Ty饻sgs{cv6Dْ80}|놱8;z\;19>%G;qZ?~'=pn&:5;c$SU'-(IUJIr擄0Vt{]AW3xK)2fkJD*(1jeT H3l3Bȥqq#9S$re ĥ$.HN/&
B쿵?n[fp0G8=
ñv
E:0#bl>8gIXHpkGԀC~aZtlxc
fla74sYg]s
vvu6p\.gt99UI~QdlOؽO^n:W'nPW&fi9fiy,S%RglƓ`3&i)8-]}4,8Afp AWN:e?"W#^vpA8œYg A@uVguO 9h&9#,-Dc'n;w3/jnHر!c`
q9!O8ҶCM']Ĝj6%t/bg1XhQ]:4'
y/8Զ5Wx8|ec?pJ\l3[!Caڈt%mUժg2l|╘@;Ϻ72۾h)77DŹOLiɇCݔpd[rpؑJO^78c`VqCU{r7 Xߛ*{G]O_2M-xȲxx'TtG5o
wD#֞A^a)!tCSOsgacxI
RY=9Vs0;!:U6Յ[`ѹ_5_DM=M&mgkck]KOyN$UBdTpDG܋|ŭ!}@!$
Q:ncGqEV_Ur?F."
-vlݲQ%'e|M~aJeVeVMd6@_\^u
>PE(_;&j'ooMJT]܉.CI4Q2CGJ4Qw$#ŕIdg|;n4Q*1yo*n6;ZTKnNSߓ7l[Wduov7.oau6,NB%-\G+8byPR{+uOf|45zv$B\Œ/"